



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

DIVISION OF  
CORPORATION FINANCE

Mail Stop: 3561

January 11, 2018

Via E-mail

Scott Myers  
President and Chief Executive Officer  
Cascadian Therapeutics, Inc.  
3101 Western Avenue, Suite 600  
Seattle, Washington 98121

**Re: Cascadian Therapeutics, Inc.  
Registration Statement on Form S-3  
Filed December 29, 2017  
File No. 333-222362**

Dear Mr. Myers:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Ruairi J. Regan, Staff Attorney, at (202) 551-3269 with any questions.

Sincerely,

/s/ David Link for

John Reynolds  
Assistant Director  
Office of Beverages,  
Apparel and Mining

cc: Robert Freedman  
Fenwick & West LLP